Entwicklung eines Lichen ruber unter adjuvanter IFN-alpha 2a-Therapie eines Malignen Melanoms
L. Kowalzick(Vogtland-Klinik), Rudolf Herbst(Helios Klinikum Erfurt), L. Eickenscheidt(Vogtland-Klinik), F. Weiße(Helios Klinikum Erfurt), J. M. Pönnighaus(Vogtland-Klinik)
Cited by 0
Related Papers
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
|The Lancet Oncology|2016|704
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
|PLoS ONE|2015|292
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
|Journal of Clinical Oncology|2019|254